Clinical Data, Inc. (NASDAQ: CLDA), a leader in the development of targeted therapeutics and predictive tests from a growing portfolio of proprietary genetic biomarkers, announced that it has initiated a long-term safety study for Vilazodone, the company’s drug candidate for the treatment of depression, ahead of schedule. [click link for full article]
Popularity: unranked [?]
Related posts:
- Clinical Data Initiates Long-Term Safety Study For Vilazodone
- Clinical Data, Inc. Initiates Second Pivotal Phase III Study Of Vilazodone
- Clinical Data, Inc. Announces Publication Of Results From First Phase III Study Of Vilazodone In Treatment Of Major Depressive Disorder
- Clinical Data, Inc. Announces Approval Of Generic Name Vilazodone, First In A New Class Of Experimental Treatments For Depression
- New Study Results Provide Additional Data About Short- And Long-Term Use Of Desvenlafaxine Succinate In The Treatment Of Major Depressive Disorder
Comments
No Responses to “Clinical Data Initiates Long-Term Safety Study For Vilazodone”